Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alligator Bioscience AB ( (SE:ATORX) ) has issued an announcement.
Alligator Bioscience AB has secured 85% of its warrant programme TO 12, with significant subscription and guarantee undertakings from key stakeholders, amounting to approximately SEK 61.6 million. This financial maneuver, along with the renegotiation of an outstanding loan, is aimed at reducing company risk and facilitating the advancement of mitazalimab towards market entry, as the company intensifies discussions with potential strategic partners.
More about Alligator Bioscience AB
Alligator Bioscience AB is a biotechnology company focused on developing innovative immuno-oncology therapies. The company is engaged in advancing its lead product candidate, mitazalimab, through strategic partnerships and regulatory alignments.
Average Trading Volume: 191,019
Current Market Cap: SEK66.54M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.